Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2022-03-21 Proxy Solicitation & In…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류). It explicitly states that it is correcting previously submitted financial statements (재무제표) for the Annual General Meeting (주주총회). Since the primary purpose of this document is to provide updated proxy materials and information for shareholders to exercise their voting rights at an upcoming meeting, it falls under the Proxy Solicitation category.
2022-03-21 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea for companies to solicit proxies from shareholders ahead of an Annual General Meeting (AGM). It contains details about the meeting agenda, voting procedures, and management information. This falls under the 'Proxy Solicitation & Information Statement' category.
2022-03-15 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) titled 'Correction Report' (정정신고) regarding a previous disclosure of 'Changes in Sales or Profit/Loss Structure of 30% or more'. It provides a comparison of financial figures before and after the correction, citing external audit results as the reason for the adjustment. This is a standard regulatory disclosure filing in the Korean market (KIND system) used to update previously released financial information. It does not fit into the specific categories of Annual Reports or Earnings Releases, but rather acts as a formal regulatory update. FY 2021
2022-03-14 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for TiumBio. It outlines the date, location, and specific agenda items (such as financial statement approval, director appointments, and remuneration limits) to be voted on by shareholders. This type of document is a standard proxy solicitation/information statement provided to shareholders prior to a meeting to request their votes and provide necessary context for the meeting agenda.
2022-03-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction filing ('정정신고'). It details the modification of stock option grants, including changes to the number of recipients and the number of shares granted. This type of disclosure regarding stock options and capital-related changes falls under the category of share issues or capital changes, which is best classified as 'SHA'.
2022-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for TiumBio. It contains the agenda for the 6th Annual General Meeting, including items such as financial statement approval, board appointments, and stock option grants. It also includes detailed management information, governance disclosures, and financial summaries required for shareholder review prior to the meeting. This document is a standard proxy statement/notice of meeting provided to shareholders to solicit votes and inform them of the upcoming AGM.
2022-03-14 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.